In a 73‑year‑old man whose depression is responding to sertraline 50 mg but who has insomnia and low libido, can I reduce the dose of Wellbutrin (bupropion) to 300 mg as the first step?

Reducing Wellbutrin to 300 mg: Not the Right First Step

Do not reduce Wellbutrin (bupropion) to 300 mg as your first intervention in this 73-year-old patient with responding depression but experiencing insomnia and low libido on sertraline 50 mg. The insomnia is likely caused by bupropion itself, and reducing the dose may compromise depression control without adequately addressing the sleep problem.

Why This Approach is Problematic

Bupropion's Activating Profile

Bupropion is inherently activating and commonly causes insomnia 1. The FDA label explicitly warns to "minimize risk of insomnia, give second dose before 3 p.m." 2. Research confirms bupropion has the highest incidence of treatment-emergent insomnia among second-generation antidepressants 3. Simply reducing from what appears to be 450 mg to 300 mg may decrease insomnia somewhat, but this medication fundamentally conflicts with your patient's sleep needs.

The Sexual Dysfunction Context

While bupropion is associated with lower rates of sexual adverse events than SSRIs like sertraline 4, and research shows it can effectively treat SSRI-induced sexual dysfunction 5, your patient's low libido may actually be multifactorial (age 73, depression itself, sertraline effects). Bupropion was likely added to address this issue, but now you're trading one problem (libido) for another (insomnia).

The Better Algorithmic Approach

Step 1: Address the Timing Issue First

• Move bupropion dosing earlier in the day if not already optimized 1
• Ensure the second dose (if using twice-daily formulation) is taken before 3 PM 2
• If using extended-release, confirm morning administration 2

Step 2: If Timing Adjustment Fails

Consider switching from bupropion to mirtazapine 1:

• Mirtazapine is "potent and well tolerated; promotes sleep, appetite, and weight gain" 1
• Dosing: 7.5 mg at bedtime, maximum 30 mg at bedtime 1
• Recent 2025 research confirms mirtazapine is "preferable for insomnia" while bupropion is "most effective for hypersomnia" 6
• This directly addresses both depression maintenance and insomnia

Step 3: Alternative - Optimize Sertraline Alone

If sexual function improves or becomes tolerable:

• Discontinue bupropion entirely (taper per FDA guidance: reduce to 150 mg before stopping if on 300 mg) 2
• Consider increasing sertraline to 100-200 mg if depression control wavers 1, 7
• Sertraline 50 mg is a low dose; the therapeutic range extends to 200 mg 1, 8

Step 4: Targeted Insomnia Management

If you must continue bupropion for depression/libido:

• Add low-dose trazodone (50-100 mg at bedtime) specifically for insomnia 9, 10
• Trazodone is widely used off-label for insomnia and is "the second most commonly prescribed agent used to treat insomnia" in the US 11
• However, guidelines note "no systematic evidence for effectiveness" and "risks may outweigh benefits" in elderly patients 10

Critical Caveats for a 73-Year-Old

Age-Related Considerations

• Elderly patients may be at greater risk for adverse effects from sedative-hypnotics due to reduced clearance 10
• Start any new medication at the lowest available dose 10
• Monitor closely for falls, cognitive impairment, and daytime sedation 10

Discontinuation Risks

• When stopping or reducing antidepressants, taper over 10-14 days to limit withdrawal symptoms 1
• The FDA label specifically instructs: "When discontinuing treatment in patients treated with Wellbutrin XL 300 mg once daily, decrease the dose to 150 mg once daily prior to discontinuation" 2

The Bottom Line

Your first step should be optimizing bupropion timing, not reducing the dose. If insomnia persists despite proper timing, the evidence strongly supports either switching to mirtazapine (which addresses both depression and insomnia) or discontinuing bupropion entirely if sertraline alone can maintain depression control. Reducing bupropion to 300 mg is a compromise that may leave you with inadequate depression treatment and persistent insomnia—the worst of both worlds.

The 2008 ACP guideline emphasizes that clinicians should "assess patient status, therapeutic response, and adverse effects on a regular basis" and "modify treatment if the patient does not have an adequate response" 4. Your patient's insomnia represents a treatment-limiting adverse effect that requires a strategic medication change, not just dose reduction.